"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
| Descriptor ID |
D011720
|
| MeSH Number(s) |
D03.383.129.539
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 1 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 3 | 0 | 3 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 4 | 1 | 5 |
| 2011 | 8 | 2 | 10 |
| 2012 | 3 | 3 | 6 |
| 2013 | 6 | 2 | 8 |
| 2014 | 5 | 4 | 9 |
| 2015 | 5 | 3 | 8 |
| 2016 | 6 | 5 | 11 |
| 2017 | 2 | 5 | 7 |
| 2018 | 5 | 3 | 8 |
| 2019 | 4 | 4 | 8 |
| 2020 | 3 | 4 | 7 |
| 2021 | 3 | 3 | 6 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024 Sep 12; 391(10):885-898.
-
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series. Clin Lung Cancer. 2023 11; 24(7):666-671.
-
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec; 18(38):4161-4170.
-
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clin Cancer Res. 2022 08 02; 28(15):3214-3224.
-
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. JCO Precis Oncol. 2022 06; 6:e2100496.
-
Lorlatinib Exposed: A Far From Optimal Dose. Clin Pharmacol Ther. 2022 06; 111(6):1195-1196.
-
A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 07; 239:180-189.
-
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).
-
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2022 02; 6:e2100448.
-
Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022 07; 179(13):3220-3234.